Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.61 |
| ▸ | MAPT | P10636 | 7/20 | 0.61 |
| ▸ | GAA | P10253 | 5/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | PTK2B | Q14289 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | THRB | P10828 | 2/20 | 0.61 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.61 |
| ▸ | RAD52 | P43351 | 2/20 | 0.54 |
| ▸ | GFER | P55789 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL187881 | 0.85 | ALDH1A1 (0.71) | ALDH1A1MAPTGAAKMT2APTK2B | |
| SCHEMBL29477783 | 0.85 | ALDH1A1 (0.71) | ALDH1A1MAPTGAAKMT2APTK2B | |
| SCHEMBL26418611 | 0.84 | HTR1A (0.49) | ALDH1A1MAPTGAAKMT2AMEN1 | |
| SCHEMBL23126590 | 0.83 | MAPT (0.54) | ALDH1A1MAPTGAAKMT2APTK2B | |
| SCHEMBL31397762 | 0.81 | ALDH1A1 (0.61) | ALDH1A1MAPTGAAKMT2APTK2B | |
| SCHEMBL15358737 | 0.81 | MAPT (0.81) | ALDH1A1MAPTGAAKMT2APTK2B | |
| SCHEMBL10126783 | 0.81 | MAPT (0.65) | ALDH1A1MAPTGAAKMT2APTK2B | |
| SCHEMBL23126654 | 0.81 | DRD2 (0.48) | ALDH1A1MAPTGAAKMT2APTK2B | |
| SCHEMBL24123866 | 0.80 | HRH3 (0.39) | ALDH1A1MAPTGAAKMT2APTK2B | |
| SCHEMBL15651152 | 0.80 | ALDH1A1 (0.55) | ALDH1A1MAPTGAAKMT2APTK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691974-B2 | 3,9-diazaspiro[5,5]undecane compound as FLT3 and AXL inhibitors | MEDSHINE DISCOVERY INC. (CN) | 2023-07-04 | — | — | US | disclosed |
| US-11691974-B2 | 3,9-diazaspiro[5,5]undecane compound as FLT3 and AXL inhibitors | MEDSHINE DISCOVERY INC. (CN) | 2023-07-04 | — | — | US | disclosed |
| US-20230141887-A1 | CRYSTAL FORM OF DIAZASPIROPYRAN COMPOUND | MEDSHINE DISCOVERY INC. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20230141887-A1 | CRYSTAL FORM OF DIAZASPIROPYRAN COMPOUND | MEDSHINE DISCOVERY INC. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20210395252-A1 | 3,9-DIAZASPIRO[5,5]UNDECANE COMPOUND AS FLT3 AND AXL INHIBITORS | MEDSHINE DISCOVERY INC. (CN) | 2021-12-23 | — | — | US | disclosed |
| EP-3572413-B1 | 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE DERIVATIVE AS WEE1 INHIBITOR | SHIJIAZHUANG SAGACITY NEW DRUG DEV CO LTD (CN) | 2021-11-03 | — | — | EP | disclosed |
| EP-3858819-A1 | 3,9- DIAZASPIRO[5,5] UNDECANE COMPOUND AS FLT3 AND AXL INHIBITORS | Medshine Discovery Inc. (CN) | 2021-08-04 | — | — | EP | disclosed |
| US-10954253-B2 | 1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one derivative as Wee1 inhibitor | Shijiazhuang Sagacity New Drug Development Co., Ltd. (CN) | 2021-03-23 | — | — | US | disclosed |
| WO-2020063856-A1 | 3,9- DIAZASPIRO[5,5] UNDECANE COMPOUND AS FLT3 AND AXL INHIBITORS | 南京明德新药研发有限公司 | 2020-04-02 | — | — | WO | disclosed |
| WO-2012053606-A1 | ARYLAMINOHETEROCYCLIC CARBOXAMIDE COMPOUND | アステラス製薬株式会社 (JP) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395252-A1 | 3,9-DIAZASPIRO[5,5]UNDECANE COMPOUND AS FLT3 AND AXL INHIBITORS | FLT3, AXL, TYRO3 | ALDH1A1 1665/4885MAPT 3594/4885GAA 1778/4885 |
| US-10954253-B2 | 1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one derivative as Wee1 inhibitor | WEE1, WEE2, CCNE1 | ALDH1A1 2046/4885MAPT 4482/4885GAA 2857/4885 |
| US-11691974-B2 | 3,9-diazaspiro[5,5]undecane compound as FLT3 and AXL inhibitors | FLT3, AXL, TYRO3 | ALDH1A1 1665/4885MAPT 3594/4885GAA 1778/4885 |
| US-20230141887-A1 | CRYSTAL FORM OF DIAZASPIROPYRAN COMPOUND | GOT1, ORMDL3, PKD1 | ALDH1A1 1925/4885MAPT 1913/4885GAA 1610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.